Janus Kinase 1 Plays a Critical Role in Mammary Cancer Progression [PDF]
Cell Reports, 2018 Summary: Janus kinases (JAKs) and their downstream STAT proteins play key roles in cytokine signaling, tissue homeostasis, and cancer development. Using a breast cancer model that conditionally lacks Janus kinase 1, we show here that JAK1 is essential ...
Barbara L. Wehde +5 more
doaj +5 more sources
Janus kinase-1 and 3 in ankylosing spondylitis
Journal of the Formosan Medical Association, 2019 Background/purpose: To investigate the Janus kinase-1 and 3 (JAK-1 and 3) expression in peripheral blood mononuclear cells (PBMCs) in ankylosing spondylitis (AS). Methods: The levels of JAK-1 and JAK-3 mRNA in PBMCs, CD3+ T cells and CD14+ monocytes were
Hsien-Tzung Liao +7 more
doaj +4 more sources
Immunohistochemistry of Janus Kinase 1 (JAK1) Expression in Vitiligo [PDF]
Journal of Pathology and Translational Medicine, 2018 Background Vitiligo is a chronic autoimmune disease in which the destruction of melanocytes causes white spots on the affected skin. Janus kinase (JAK) is a family of intracellular, non-receptor tyrosine kinases that transduce cytokine-mediated signals ...
Asmaa Gaber Abdou +3 more
doaj +5 more sources
Evaluation of immunohistochemical and gene expression of Janus kinase 1 and Janus kinase 3 in the skin of different clinical types of mycosis fungoides patients - Part I [PDF]
Anais Brasileiros de DermatologiaBackground Mycosis fungoides is the commonest type of cutaneous T-Cell lymphoma. Janus kinases are intracellular tyrosine kinases that have recently been proven to have a crucial role in the pathogenesis and progression of several dermatological and ...
Heba Saed El-Amawy +3 more
doaj +4 more sources
The Janus kinase 1 is critical for pancreatic cancer initiation and progression [PDF]
Cell ReportsSummary: Interleukin-6 (IL-6)-class inflammatory cytokines signal through the Janus tyrosine kinase (JAK)/signal transducer and activator of transcription (STAT) pathway and promote the development of pancreatic ductal adenocarcinoma (PDAC); however, the
Hridaya Shrestha +13 more
doaj +4 more sources
Ruxolitinib suppresses liver fibrosis progression and accelerates fibrosis reversal via selectively targeting Janus kinase 1/2 [PDF]
Journal of Translational Medicine, 2022 Background JAK1 and JAK2 have been implicated in fibrosis and cancer as a fibroblast-related marker; however, their role in liver fibrosis has not been elucidated.
Zhenghui Song +8 more
doaj +2 more sources
Ruxolitinib: An Oral Janus Kinase 1 and Janus Kinase 2 Inhibitor in the Management of Myelofibrosis [PDF]
Postgraduate Medicine, 2013 Myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET) are referred to as the classic Philadelphia chromosome (BCR-ABL1)-negative myeloproliferative neoplasms. Although each has distinct pathologic features, all 3 display alterations in Janus kinase (JAK) signal transduction activator of transcription signaling. Myelofibrosis is
Srdan Verstovšek
exaly +3 more sources
Evaluation of immunohistochemical and gene expression of Janus kinase 1 and Janus kinase 3 in the skin of different clinical types of mycosis fungoides patients - Part II: reverse transcriptase-polymerase chain reaction [PDF]
Anais Brasileiros de DermatologiaBackground Mycosis Fungoides (MF) is the commonest type of primary cutaneous T-Cell lymphomas representing about 50% of all lymphomas arising primarily in the skin. Janus kinases are non-receptor intracellular tyrosine kinases that play an important role
Heba Saed El-Amawy +3 more
doaj +3 more sources
The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 [PDF]
Leukemia, 2020 La Rosee F, Bremer HC, Gehrke I, Kehr A, Hochhaus A, Birndt S, et al. The Janus kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation. Leukemia. 2020;34:1805–15. https://doi.org/10.1038/s41375-020-0891-0. CAS Article PubMed Google Scholar Download references Division of Hematology, University of Siena, Siena, Italy ...
Gozzetti, Alessandro +2 more
openaire +5 more sources
Inhibition of Janus Kinase 1 synergizes docetaxel sensitivity in prostate cancer cells [PDF]
Journal of Cellular and Molecular Medicine, 2021 AbstractProstate cancer (PCa) is the second most common malignancy and is the fifth leading cause of cancer mortality among men globally. Docetaxel‐based therapy remains the first‐line treatment for metastatic castration‐resistant prostate cancer. However, dose‐limiting toxicity including neutropenia, myelosuppression and neurotoxicity is the major ...
Geetha Nalairndran +8 more
openaire +4 more sources